Joshua Santos

Dr. Joshua Santos

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JSJoshua Santos
Joshua Santos
MQMark Tristan Quimque
Mark Tristan Quimque
AMALLAN PATRICK MACABEO
ALLAN PATRICK MACABEO
MCMary Jho-Anne T. Corpuz
Mary Jho-Anne T. Corpuz
YWYun-Ming Wang
Yun-Ming Wang
OVOliver Villaflores
Oliver Villaflores
Bioavailability plays an important role in drug activity in the human body, as certain drug amounts should be present to elicit activity. However, low bioavailability of drugs leads to negligible use for human benefit. In this study, the diversely active neolignan, magnolol, was impregnated onto a Zr-based organometallic framework [Uio-66(Zr)] to increase its low bioavailability (4–5%) and to test its potential acute oral toxicity. Synthesis of Uio-66(Zr) was done through the solvothermal method while simple impregnation at different time points was used to incorporate magnolol. The loading capacity of Uio-66(Zr) at 36 h was found to be significantly higher at 72.16 ± 2.15% magnolol than in other incubation time. Based on the OECD 425 (limit test), toxicity was not observed at 2000 mg kg−1 dose of mag@Uio-66(Zr) in female Sprague Dawley rats. The area under the curve (AUC) at 0–720 min of mag@Uio-66(Zr) was significantly higher than the AUC of free magnolol. Moreover, relative bioavailability increased almost two-folds using Uio-66(Zr). Unconjugated magnolol was found in the liver, kidney, and brain of rats in all treatment groups. Collectively, Uio-66(Zr) provided a higher magnolol bioavailability when used as drug carrier. Thus, utilization of Uio-66(Zr) as drug carrier is of importance for maximal use for poorly soluble and lowly bioavailable drugs.

14 September 2021 in ACS Omega
Verified
Journal Article
Open access
JSJoshua Santos
Joshua Santos
MQMark Tristan Quimque
Mark Tristan Quimque
RLRhenz Alfred Liman
Rhenz Alfred Liman
JAJay Carl Agbay
Jay Carl Agbay
AMALLAN PATRICK MACABEO
ALLAN PATRICK MACABEO
OVOliver Villaflores
Oliver Villaflores
The phenolic natural product magnolol exhibits neuroprotective properties through β-amyloid toxicity in PC-12 cells and ameliorative effects against cognitive deficits in a TgCRND8 transgenic mice model. Its bioavailability and blood–brain barrier crossing ability have been significantly improved using the metal–organic framework (MOF) UiO-66(Zr) as a drug delivery system (DDS). To investigate the neuroprotective effects of the Zr-based DDS, magnolol and magnolol-loaded-UiO-66(Zr) ([email protected](Zr)) were evaluated for inhibitory activity against β-secretase and AlCl3-induced neurotoxicity. Due to the moderate inhibition observed for magnolol in vitro, in silico binding studies were explored against β-secretase along with 11 enzymes known to affect Alzheimer’s disease (AD). Favorable binding energies against CDK2, CKD5, MARK, and phosphodiesterase 3B (PDE3B) and dynamically stable complexes were noted through molecular docking and molecular dynamic simulation experiments, respectively. The magnolol-loaded DDS UiO-66(Zr) also showed enhanced neuroprotective activity against two pathological indices, namely, neutrophil infiltration and apoptotic neurons, in addition to damage reversal compared to magnolol. Thus, MOFs are promising drug delivery platforms for poorly bioavailable drugs.

1 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JSJoshua Santos
Joshua Santos
HVHannah Jean Victoriano
Hannah Jean Victoriano
MSMary Sepulveda
Mary Sepulveda
HLHung-En Liu
Hung-En Liu
SVShierrie Mae N. Valencia
Shierrie Mae N. Valencia
Chia-Her LinChia-Her Lin
Chia-Her Lin
Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases, including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low oral bioavailability, limiting therapeutic potential. This study aimed to enhance its oral bioavailability using MIL-100(Fe), a metal–organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 h. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 423 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 MIL-100(Fe) to syringic acid ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1239.2 cm−1), and TGA indicated thermal stability at ~350 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and a 12.82-fold increase compared to intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.

24 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JSJoshua Santos
Joshua Santos
HVHannah Jean Victoriano
Hannah Jean Victoriano
MSMary Sepulveda
Mary Sepulveda
HLHung-En Liu
Hung-En Liu
SVShierrie Mae Valencia
Shierrie Mae Valencia
Chia-Her LinChia-Her Lin
Chia-Her Lin
Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low bioavailability, limiting therapeutic potential. This study aimed to enhance its bioavailability using MIL-100(Fe), a metal-organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 hours. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 425 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 syringic acid to MIL-100(Fe) ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1242 cm⁻¹), and TGA indicated thermal stability at ~450 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and 12.82-fold over intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.

28 February 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JSJoshua Santos
Joshua Santos
HVHannah Jean Victoriano
Hannah Jean Victoriano
MSMary Sepulveda
Mary Sepulveda
HLHung-En Liu
Hung-En Liu
SVShierrie Mae N. Valencia
Shierrie Mae N. Valencia
Chia-Her LinChia-Her Lin
Chia-Her Lin
Background/Objectives: The use of the drug delivery system is notable for the systemic improvement of low orally bioavailable compounds, such as the bioactive phenolic acid, syringic acid. Innovative techniques are employed to enhance the performance of certain drug delivery systems. In connection with our previously reported journal with the use of MIL-100(Fe) as a drug carrier for syringic acid, this study utilized a mixed-linker synthesis of syringic acid and trimesic acid and characterized the properties in comparison with the unmodified MIL-100(Fe) through a solid solution approach. Methods: Modified MIL-100(Fe) was synthesized by substituting different molar concentrations of syringic acid for trimesic acid through de novo synthesis. Simple impregnation of syringic acid was carried out at 12, 24, 36, and 48 h and at 1:1 and 1:2 molar ratios of MIL-100(Fe) to syringic acid. Characterization was performed via PXRD, FTIR, BET, SEM, and DLS. In vivo studies included acute oral toxicity testing (OECD 425) and bioavailability assessment in Sprague Dawley rats. Results: The optimized amount of syringic acid to be substituted for trimesic acid is 0.10 mmol, as confirmed by the value of the PXRD. Optimized drug loading of 66.85 ± 0.004% was achieved using a 1:2 ratio of syringic acid to MIL-100(Fe)-10% over 36 h. Structural modifications were confirmed via FTIR, specifically through shifts at 1239.2 cm−1, while TGA demonstrated thermal stability up to approximately 350 °C. Morphological analysis by SEM showed octahedral particles (210.70 ± 1.23 nm), and a decrease in BET surface area post-loading verified successful encapsulation. While in vitro release was media-dependent, toxicity studies at 2000 mg/kg showed no adverse effects; notably, SGOT and SGPT levels decreased, though BUN and creatinine levels rose. Compared to pure oral syringic acid, the SYA@MIL-100(Fe)-10% formulation demonstrated a 5.09-fold increase in relative bioavailability. Furthermore, it outperformed intraperitoneal administration of the drug by 1.65-fold. Conclusions: Modification of MIL-100(Fe) by incorporating syringic acid into the framework as a substituted organic linker indicates that SYA@MIL-100(Fe)-10% is a safe and effective delivery system for syringic acid, enhancing oral bioavailability. To the best of our knowledge, this is the first study to investigate the mixed-linker synthesis of MIL-100(Fe) by utilizing syringic acid as a structural co-ligand, rather than solely as an encapsulated guest. While MIL-100(Fe) has been extensively employed as a carrier for various therapeutics, this research uniquely integrates the active agent into the framework lattice itself to modulate porosity and loading capacity, subsequently evaluating its systemic performance in an in vivo model.

1 July 2018 in Philippine Journal of Health Research and Development
Verified
Journal Article
Open access
JSJoshua Santos
Joshua Santos
MOMarina Osi
Marina Osi
MCMary Jho-Anne Corpuz
Mary Jho-Anne Corpuz
OVOliver Villaflores
Oliver Villaflores
Background: Glutathione is a major antioxidant in the body that serves as a substrate for conjugation reactions and regulates cell proliferation. Low levels of glutathione have been linked to cancer, liver problems and other chronic diseases. Studies have shown that oral supplementation is not effective in increasing the glutathione level in the body. Objectives: The purpose of the study was to prepare a niosomal formulation of glutathione and to characterize the niosomal formulation. Furthermore, the study compared the effect of the charge inducer in the formulation. Methodology: The method was divided to the preparation, characterization and stability study of the niosomal formulation. The niosomal formulation was produced by thin film hydration with varying Span 60 (Sorbitan monostearate) and cholesterol ratios. Niosomal formulation with highest entrapment efficiency was further characterized for mean particle size, surface morphology, and in vitro drug release. Results and Discussion: Formulation A entrapped 98.21% of the glutathione. Addition of charge inducer increased its entrapment efficiency to 98.91%. Furthermore, both niosomal formulations released glutathione at pH 7.4 in 1.0M phosphate buffer saline (PBS). The mean vesicular size obtained was 1,242.97 + 40.52nm. Differential Scanning Calorimetry revealed compatibility between glutathione and its excipients. Both formulations do not cause cytotoxicity in human dermal fibroblast. The stability study also revealed that it was stable at 5°C and 40°C for 3 months. Conclusion: Results of this study suggested the potential use of niosomes in the targeted delivery of glutathione. This is the first report on the use of niosomal preparations through thin film hydration technique in the delivery of reduced L-glutathione.